Table 4.
Primary and secondary endpoints and clinical outcomes.
| SALINE (n = 16) |
SCT (n = 16) |
p-Value | |
|---|---|---|---|
| STR > 70% | 12 (75.0%) | 3 (18.8%) | 0.004 |
| Final TIMI flow 3 with MBG ˃ 1 | 14 (87.5%) | 7 (43.8%) | 0.023 |
| Final TIMI flow 3 with MBG ≤ 1 or TIMI ˂ 3 | 2 (12.6%) | 9 (56.3%) | - |
| Combined STR and angiographic MVO resolution | 10 (62.5%) | 1 (6.3%) | <0.001 |
| LVEF at discharge, % | 52.9 ± 8.8 | 55.8 ± 11.4 | 0.478 |
| Hs-TnI (ng/L) peak | 76.821 ± 69.402 [IQR 29544, 86250] |
79.989 ± 78.261 [IQR 29932, 133549] |
0.720 |
| MACCE at 3 years | 1 (6.3%) | 8 (50.0%) | 0.047 |
| Cardiovascular death | 0 | 0 | |
| MI | 0 | 1 (6.3%) | |
| TLR | 0 | 2 (12.5%) | |
| HF hospitalization | 1 (6.3%) | 3 (18.8%) | |
| CVE | 0 | 2 (12.5%) | |
| LVEF Δ* at 1 year | +6.8 ± 8.5 | +5.6 ± 11.4 | 0.728 |
| Any Bleeding | 0 | 1 (6.3%) | - |
* = considering the difference between values at baseline and 1-year follow-up. Abbreviations: CVE = cerebro-vascular events; HF = heart failure; Hs-TnI: high-sensitivity troponin I; LVEF = left ventricular ejection fraction; MACE = major adverse cardiac events; MACCE = major adverse cardiac and cerebro-vascular events; MBG = myocardial blush grade; MI = myocardial infarction; MVO = microvascular obstruction; pPCI = percutaneous primary coronary intervention; MBG = myocardial blush grade; SCT = standard care of therapy; STR: ST resolution; TIMI = thrombolysis in myocardial infarction; TLR = target lesion revascularization.